Related Experiment Video
Updated: May 24, 2026

Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Cardiac hormones are c-Jun-N-terminal kinase 2-inhibiting peptides
Meghan L Lane1, Omar Santana, Chelsea D Frost
1Department of Medicine, James A. Haley VA Medical Center, University of South Florida for Health Sciences, Tampa, FL, USA.
Background:
Four cardiac peptide hormones, namely vessel dilator, long-acting natriuretic peptide (LANP), kaliuretic peptide, and atrial natriuretic peptide (ANP) have anticancer effects.
Materials And Methods:
The effects of these four cardiac hormones on human c-Jun-N-terminal kinase 2 (JNK2) were examined in human small cell lung cancer and human prostate cancer cells.
Results:
Vessel dilator, LANP, kaliuretic peptide and ANP maximally reduced expression of JNK2 by 89%, 56%, 45%, and 28%, respectively (each at p<0.0001) in human small cell lung cancer cells. In human prostate adenocarcinoma cells, JNK2 was maximally decreased 76%, 56%, 45%, (each at p<0.0001), and 28% (p<0.01) secondary to vessel dilator, LANP, kaliuretic peptide and ANP, respectively.
Conclusion:
These results indicate that four cardiac hormones are significant inhibitors (by up to 89%) of JNK2 in human small cell lung cancer cells and up to 76% in human prostate adenocarcinoma cells as part of their anticancer mechanism(s) of action.
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Secondary Messengers in Hormone Action
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
G-Protein Gated Ion Channels
Sensory organs,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antihypertensive Drugs: Action of β1 Blockers

